SCHEMBL20091675

SCHEMBL20091675

Cc1cccc(F)c1N(C)S(C)(=O)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
POLB P06746 2/20 0.41
ACHE P22303 1/20 0.40
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
STS P08842 1/20 0.38
RECQL P46063 1/20 0.37
HTT P42858 2/20 0.36
PTK2 Q05397 1/20 0.36
KDM4E B2RXH2 1/20 0.36
TSHR P16473 2/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
KEAP1 Q14145 1/20 0.34
NFE2L2 Q16236 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26514001 0.86 ALDH1A1 (0.44) ALDH1A1POLBPTK2KDM4ETSHR
SCHEMBL26122242 0.80 CYP19A1 (0.35) ALDH1A1RECQLTSHRKMT2ATDP1
SCHEMBL4679730 0.80 KMT2A (0.38) ALDH1A1POLBRECQLHTTLMNA
SCHEMBL20155932 0.79 RECQL (0.41) ALDH1A1RECQLHTTMEN1LMNA
SCHEMBL23637881 0.78 ESR1 (0.43) ALDH1A1POLBPTK2KDM4ETSHR
SCHEMBL26512157 0.78 ALDH1A1 (0.40) ALDH1A1POLBPTK2KDM4ELMNA
SCHEMBL26118807 0.78 CD44 (0.42) ALDH1A1POLBPTK2KDM4ETSHR
SCHEMBL24497694 0.77 PTK2 (0.46) ALDH1A1POLBPTK2KDM4ETSHR
SCHEMBL24498552 0.77 ALDH1A1 (0.35) ALDH1A1RECQLHTTMEN1MAPK1
SCHEMBL20073210 0.77 POLB (0.38) POLBRECQLTSHRLMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4257587-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2023-10-11 EP disclosed
US-20220073527-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-03-10 US disclosed
EP-3848370-A2 TYK2 INHIBITORS AND USES THEREOF Nimbus Lakshmi, Inc. (US) 2021-07-14 EP disclosed
WO-2018075937-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2018-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073527-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 ALDH1A1 4827/4885POLB 1657/4885ACHE 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.